What question did this study set out to answer?

To review the contribution of drug tolerability and adverse effect profiles to poor treatment adherence and inadequate blood pressure control across major antihypertensive drug classes.

November 1, 2001American Journal of Hypertension

Issues in hypertension: drug tolerability and special populations

View Full Paper

Ask AI

Bookmark

Why the study?

Do angiotensin receptor blockers (ARBs) like eprosartan improve tolerability and blood pressure control compared to other antihypertensive agents in patients with hypertension?

Key Points

To review the contribution of drug tolerability and adverse effect profiles to poor treatment adherence and inadequate blood pressure control across major antihypertensive drug classes.
Narrative synthesis evaluating adherence patterns and adverse effect profiles of diuretics, beta-blockers, calcium channel blockers, and ACE inhibitors.
Comparative assessment of angiotensin receptor blockers, highlighting clinical trial data for eprosartan and preliminary findings from the ELITE trial.
Adequate blood pressure control (<140/90 mm Hg) is achieved in only 29% of treated hypertensive Americans, with nearly half of hypertensive individuals receiving no therapy.
ACE inhibitors cause cough in up to 19% of treated patients, whereas angiotensin receptor blockers demonstrate adverse effect profiles similar to placebo.
Eprosartan achieves blood pressure response rates that rival or exceed enalapril while offering improved tolerability.

Structured PICO

Do angiotensin receptor blockers (ARBs) like eprosartan improve tolerability and blood pressure control compared to other antihypertensive agents in patients with hypertension?

Population

Patients with hypertension

Intervention

Angiotensin receptor blockers (ARBs), specifically eprosartan

Comparator

Other antihypertensive agents (ACE inhibitors, diuretics, beta-blockers, calcium channel blockers) or placebo

Outcome

Blood pressure control and drug tolerability/side effect profile

ARBs such as eprosartan provide an effective and highly tolerable alternative for hypertension management, particularly for patients experiencing side effects from other antihypertensive classes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports ARB use in ACEI-intolerant patients; leaves open need for updated comparative trials versus contemporary agents.

Cite This Study

Haralambos Gavras (2001) studied this question.

synapsesocial.com/papers/6a771551a0847c3df1ec52db https://doi.org/10.1016/s0895-7061(01)02132-x

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Issues in hypertension: drug tolerability and special populations

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Issues in hypertension: drug tolerability and special populations

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider